反义寡核苷酸和小干扰RNA寡核苷酸治疗的生物学障碍。
Biological barriers to therapy with antisense and siRNA oligonucleotides.
作者信息
Juliano R, Bauman J, Kang H, Ming X
机构信息
UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA.
出版信息
Mol Pharm. 2009 May-Jun;6(3):686-95. doi: 10.1021/mp900093r.
Abstract
Attaining the full therapeutic utility of antisense and siRNA oligonucleotides will require understanding of the biological barriers that stand between initial administration of these drugs and their final actions within cells. This review examines some of the key barriers that affect the biodistribution of oligonucleotides both in molecular form and when they are associated with nanocarriers. An understanding of the biological processes underlying these barriers will aid in the design of more effective delivery systems.
摘要
要实现反义寡核苷酸和小干扰RNA寡核苷酸的全部治疗效用，需要了解这些药物初始给药与它们在细胞内的最终作用之间存在的生物屏障。本综述探讨了一些影响寡核苷酸分子形式及其与纳米载体结合时生物分布的关键屏障。了解这些屏障背后的生物学过程将有助于设计更有效的递送系统。
相似文献
1
Biological barriers to therapy with antisense and siRNA oligonucleotides.反义寡核苷酸和小干扰RNA寡核苷酸治疗的生物学障碍。
Mol Pharm. 2009 May-Jun;6(3):686-95. doi: 10.1021/mp900093r.
2
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.有效递送反义寡核苷酸和小干扰RNA的机制与策略
Nucleic Acids Res. 2008 Jul;36(12):4158-71. doi: 10.1093/nar/gkn342. Epub 2008 Jun 16.
3
Targeting the lung using siRNA and antisense based oligonucleotides.使用基于小干扰RNA（siRNA）和反义的寡核苷酸靶向肺部。
Curr Pharm Des. 2008;14(34):3620-7. doi: 10.2174/138161208786898851.
4
Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.用于递送反义寡核苷酸和小干扰 RNA 的（纳米）制剂设计的进展：聚焦于中枢神经系统。
Mol Pharm. 2021 Apr 5;18(4):1491-1506. doi: 10.1021/acs.molpharmaceut.0c01238. Epub 2021 Mar 18.
5
Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug.siRNA、反义寡核苷酸和抗癌药物的气管内与静脉内脂质体递送
Pharm Res. 2009 Feb;26(2):382-94. doi: 10.1007/s11095-008-9755-4. Epub 2008 Oct 29.
6
Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.反义药效学：反义寡核苷酸转运与递送中的关键问题。
Pharm Res. 1999 Apr;16(4):494-502. doi: 10.1023/a:1011958726518.
7
Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.大鼠体内小干扰RNA的中枢给药：与反义寡核苷酸的比较。
Eur J Pharmacol. 2005 Oct 17;522(1-3):30-7. doi: 10.1016/j.ejphar.2005.08.021. Epub 2005 Oct 6.
8
Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides.用于递送小干扰RNA和反义寡核苷酸的生物相容性透明质酸阳离子衍生物
J Drug Target. 2009 Feb;17(2):123-32. doi: 10.1080/10611860802472461.
9
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.聚合物纳米载体递送反义寡核苷酸和小干扰RNA的研究现状与展望
Int J Pharm. 2008 Dec 8;364(2):237-48. doi: 10.1016/j.ijpharm.2008.06.011. Epub 2008 Jun 19.
10
Oral delivery of siRNA and antisense oligonucleotides.小干扰RNA和反义寡核苷酸的口服递送。
J Drug Target. 2009 Aug;17(7):491-5. doi: 10.1080/10611860903057674.
引用本文的文献
1
Biological Evaluation of Molecular Spherical Nucleic Acids: Targeting Tumors via a Hybridization-Based Folate Decoration.分子球形核酸的生物学评估：通过基于杂交的叶酸修饰靶向肿瘤
ACS Omega. 2025 Feb 4;10(6):6003-6014. doi: 10.1021/acsomega.4c10047. eCollection 2025 Feb 18.
2
Synthesis of New Polyfluoro Oligonucleotides via Staudinger Reaction.通过施陶丁格反应合成新型多氟寡核苷酸。
Int J Mol Sci. 2024 Dec 31;26(1):300. doi: 10.3390/ijms26010300.
3
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates.抗乙型肝炎病毒的高级 siRNA 递呈：机制见解和最新进展。
J Nanobiotechnology. 2024 Nov 30;22(1):745. doi: 10.1186/s12951-024-03004-3.
4
Advancing cancer treatments: The role of oligonucleotide-based therapies in driving progress.推进癌症治疗：基于寡核苷酸的疗法在推动进展中的作用。
Mol Ther Nucleic Acids. 2024 Jun 17;35(3):102256. doi: 10.1016/j.omtn.2024.102256. eCollection 2024 Sep 10.
5
Delivering CRISPR to the HIV-1 reservoirs.将CRISPR技术应用于HIV-1病毒库。
Front Microbiol. 2024 May 15;15:1393974. doi: 10.3389/fmicb.2024.1393974. eCollection 2024.
6
MicroRNA-26a in respiratory diseases: mechanisms and therapeutic potential.微小 RNA-26a 在呼吸疾病中的作用机制与治疗潜力
Mol Biol Rep. 2024 May 8;51(1):627. doi: 10.1007/s11033-024-09576-5.
7
Co-delivery of fucoxanthin and Twist siRNA using hydroxyethyl starch-cholesterol self-assembled polymer nanoparticles for triple-negative breast cancer synergistic therapy.使用羟乙基淀粉-胆固醇自组装聚合物纳米颗粒共递送岩藻黄质和Twist小干扰RNA用于三阴性乳腺癌的协同治疗。
J Adv Res. 2025 Apr;70:463-479. doi: 10.1016/j.jare.2024.04.017. Epub 2024 Apr 16.
8
Targeting and engineering long non-coding RNAs for cancer therapy.靶向并改造长链非编码RNA用于癌症治疗。
Nat Rev Genet. 2024 Aug;25(8):578-595. doi: 10.1038/s41576-024-00693-2. Epub 2024 Feb 29.
9
A Convenient Oligonucleotide Conjugation via Tandem Staudinger Reaction and Amide Bond Formation at the Internucleotidic Phosphate Position.通过在核苷酸间磷酸位置的串联 Staudinger 反应和酰胺键形成进行方便的寡核苷酸偶联。
Int J Mol Sci. 2024 Feb 7;25(4):2007. doi: 10.3390/ijms25042007.
10
Self-Penetrating Oligonucleotide Derivatives: Features of Self-Assembly and Interactions with Serum and Intracellular Proteins.自穿透寡核苷酸衍生物：自组装特征及其与血清和细胞内蛋白质的相互作用
Pharmaceutics. 2023 Dec 14;15(12):2779. doi: 10.3390/pharmaceutics15122779.
本文引用的文献
1
siRNA as a tool for investigating organogenesis: The pitfalls and the promises.siRNA 作为研究器官发生的工具：陷阱与承诺。
Organogenesis. 2008 Jul;4(3):176-81. doi: 10.4161/org.4.3.6642.
2
Increased RNAi is related to intracellular release of siRNA via a covalently attached signal peptide.RNA干扰增强与通过共价连接的信号肽实现的小干扰RNA的细胞内释放有关。
RNA. 2009 Apr;15(4):627-36. doi: 10.1261/rna.1305209. Epub 2009 Feb 18.
3
In vivo SPECT and real-time gamma camera imaging of biodistribution and pharmacokinetics of siRNA delivery using an optimized radiolabeling and purification procedure.使用优化的放射性标记和纯化程序对siRNA递送的生物分布和药代动力学进行体内单光子发射计算机断层扫描（SPECT）和实时γ相机成像。
Bioconjug Chem. 2009 Jan;20(1):174-82. doi: 10.1021/bc800408g.
4
Delivery of siRNA to the target cell cytoplasm: photochemical internalization facilitates endosomal escape and improves silencing efficiency, in vitro and in vivo.将小干扰RNA（siRNA）递送至靶细胞胞质：光化学内化促进内体逃逸并提高体内外沉默效率。
Curr Pharm Des. 2008;14(34):3686-97. doi: 10.2174/138161208786898789.
5
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.针对载脂蛋白B-100的第二代反义寡核苷酸体内药代动力学/药效学关系的跨物种比较。
Biochem Pharmacol. 2009 Mar 1;77(5):910-9. doi: 10.1016/j.bcp.2008.11.005. Epub 2008 Nov 14.
6
Exploring the full spectrum of macrophage activation.探索巨噬细胞激活的全谱。
Nat Rev Immunol. 2008 Dec;8(12):958-69. doi: 10.1038/nri2448.
7
Chemical modification of siRNAs for in vivo use.用于体内应用的小干扰RNA的化学修饰
Oligonucleotides. 2008 Dec;18(4):305-19. doi: 10.1089/oli.2008.0164.
8
Cellular delivery and biological activity of antisense oligonucleotides conjugated to a targeted protein carrier.与靶向蛋白载体偶联的反义寡核苷酸的细胞递送及生物学活性
Bioconjug Chem. 2008 Nov 19;19(11):2182-8. doi: 10.1021/bc800270w.
9
Factors affecting the clearance and biodistribution of polymeric nanoparticles.影响聚合物纳米颗粒清除率和生物分布的因素。
Mol Pharm. 2008 Jul-Aug;5(4):505-15. doi: 10.1021/mp800051m. Epub 2008 Aug 4.
10
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.有效递送反义寡核苷酸和小干扰RNA的机制与策略
Nucleic Acids Res. 2008 Jul;36(12):4158-71. doi: 10.1093/nar/gkn342. Epub 2008 Jun 16.
Zotero 插件